MacroGenics reported $-13.85M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Amgen USD 4.68B 65M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Genmab DKK 407M 182M Jun/2026
Geron USD 5.73M 18.38M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Merck USD 7.33B 6.49B Sep/2026
Pfizer USD 662M 5M Sep/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Xencor USD -36.6M 41.26M Jun/2026